DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for trichinosis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTrichinosis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for trichinosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
nuclear receptor subfamily 3 group C member 1 (NR3C1) — NR3C1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7KW7 · 3.57 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Cortisone and ACTH were tested in clinical trials for trichinosis from 1951 onward. The authors of a 1958 review reported that these drugs provided "significant relief of symptoms": decrease in fever and eosinophilia, increased muscular strength, and lessening of pain and fatigue. No numbers of patients or response rates are given in that abstract, and the authors note that no anthelminthic drug had been shown effective in the intramuscular phase of the disease. The same review states that the mortality rate in cases coming to medical attention was about 5 per cent, and that most infections were subclinical.
A 1940 study of seventy patients who had recovered from acute trichinosis found that nine (12.9 per cent) had residual symptoms for varying periods. Those symptoms were ready fatigue of the muscles, especially of the calves, and some muscle soreness. All symptoms disappeared after about one year even in the worst cases, according to that study.
A 1993 description of trichinosis explains that the disease is caused by the nematode Trichinella spiralis and that the pathological changes follow three stages: penetration of adult female worms into the intestinal mucosa, migration of juvenile worms, and penetration of juvenile worms with subsequent encystment in muscle cells. A 1940 autopsy study of 300 cases at the University Hospital in Ann Arbor reported the incidence of trichinosis in that sample, but no treatment data are given. A 2010 fact sheet discusses prevention through safe food handling but provides no new clinical trial results.
What is still missing is any controlled trial with a defined sample size and quantitative outcomes for cortisone or ACTH in trichinosis, and any evidence that these drugs alter the course of the infection rather than just symptoms. No trial has tested whether they reduce the rate of encystment or shorten the duration of residual symptoms. Funding for such a trial, a clear definition of which patients might benefit, and a design that separates symptomatic relief from true disease modification are all absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Tropical Medicine and Hygiene · 1958 · 9 citations
Studies on the Use of Cortisone and Acth in Trichinosis
AbstractIntroduction. The incidence of trichinosis in the general population of the United States is thought to be about 25 per cent, but may be as high as 35 per cent in some regions. Most cases, however, are subclinical and go unrecognized. In those cases which come to medical attention the mortality rate is about 5 per cent. No specific therapy is known, and the treatment is symptomatic (Gould, 1945). In recent years clinical trials have shown all the anthelminthic drugs to be ineffective in the intramuscular phase of this disease.Since 1951, clinical studies on the use of ACTH and cortisone have yielded data showing that these drugs are valuable in the treatment of trichinosis (Buyella et al., 1953; Davis and Most, 1951; Faiguenbaum, 1952; Rosen, 1952; Rothenberg, 1951; Sadusk, 1954; Solomon and Seligman, 1952). Significant relief of symptoms has been reported: decrease in fever and eosinophilia, increased muscular strength, and a lessening of pain and fatigue.
American Journal of Tropical Medicine and Hygiene · 1940 · 6 citations
Residual Symptoms in Patients Following Recovery from Acute Infestation with Trichinosis 1
AbstractSummaryTwenty-four patients replied to the questionnaire and forty-six have been observed over a period covering recovery from acute trichinosis to two years after recovery from this disease, making a total of seventy patients in all who have been studied. Of these patients, nine or 12.9 per cent showed residual symptoms for varying periods of time. These symptoms included ready fatigue of the muscles, especially of the calves, and some muscle soreness. All symptoms, as far as could be discovered, disappeared after about one year even in the worst cases.
Cambridge University Press eBooks · 1993 · 1 citations
Trichinosis
AbstractTrichinosis, also known as trichinellosis, trichiniasis, or trichinelliasis, is a disease of humans and of other mammals infected with the nematode worm Trichinella spiralis. The pathological changes and the symptomatology of Trichinella infection are manifestations of three successive stages in the life history of the worm: (1) penetration of adult female worms into the intestinal mucosa, (2) migration of juvenile worms, and (3) penetration of juvenile worms and subsequent encystment in muscle cells.
American Journal of Epidemiology · 1940 · 0 citations
THE INCIDENCE OF TRICHINOSIS IN 300 AUTOPSIES AT THE UNIVERSITY HOSPITAL, ANN ARBOR, MICHIGAN1
AbstractJournal Article THE INCIDENCE OF TRICHINOSIS IN 300 AUTOPSIES AT THE UNIVERSITY HOSPITAL, ANN ARBOR, MICHIGAN Get access LLOYD CATRON LLOYD CATRON Search for other works by this author on: Oxford Academic PubMed Google Scholar American Journal of Epidemiology, Volume 32-SectionD, Issue 1, July 1940, Pages 12–23, https://doi.org/10.1093/oxfordjournals.aje.a118676 Published: 01 July 1940
Cause of Trichinosis and its Prevention Through Safe Food Handling Practices
AbstractFSHN10-05, a 5-page fact sheet by Alina Balaguero and Keith R. Schneider, discusses Trichinosis, an infection caused by the foodborne pathogen Trichinella, and provides information on preventing the infection, recognizing symptoms, and receiving treatment. Includes references. Published by the UF Department of Food Science and Human Nutrition, June 2010. FSHN10-05/FS153: The Cause of Trichinosis and Its Prevention Through Safe Food Handling Practices (ufl.edu)
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
